First Trust Advisors LP Has $2.81 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

First Trust Advisors LP trimmed its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 21.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 77,901 shares of the medical device company's stock after selling 21,204 shares during the period. First Trust Advisors LP owned 0.12% of Tandem Diabetes Care worth $2,806,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock worth $8,379,000 after purchasing an additional 113,355 shares during the period. Smartleaf Asset Management LLC increased its position in Tandem Diabetes Care by 163.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after buying an additional 1,101 shares during the period. US Bancorp DE lifted its stake in Tandem Diabetes Care by 15.2% in the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after buying an additional 5,108 shares during the last quarter. KBC Group NV boosted its holdings in shares of Tandem Diabetes Care by 41.5% during the fourth quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock valued at $6,933,000 after acquiring an additional 56,461 shares during the period. Finally, Envestnet Portfolio Solutions Inc. grew its position in shares of Tandem Diabetes Care by 22.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after acquiring an additional 1,184 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have issued reports on TNDM. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $35.00 to $25.00 in a research note on Friday, February 28th. Royal Bank of Canada lowered their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Barclays cut their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Stifel Nicolaus decreased their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Canaccord Genuity Group lifted their price objective on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $39.81.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.90% of the company's stock.

Tandem Diabetes Care Trading Up 4.4 %

NASDAQ TNDM traded up $0.94 on Wednesday, hitting $22.26. 1,473,406 shares of the stock were exchanged, compared to its average volume of 1,501,329. The company's 50-day moving average price is $18.55 and its two-hundred day moving average price is $28.38. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.69. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of -11.53 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business's revenue for the quarter was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) earnings per share. Research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.